Your Cholesterol Looks Fine. But What About Lp(a)?

The updated 2026 joint guidelines from the American College of Cardiology and American Heart Association now recommend that every adult have their Lp(a) measured at least once as part of cardiovascular risk assessment.

What Exactly Is Lp(a)?

Lp(a) is a type of lipoprotein — a fatty protein particle that carries cholesterol through your bloodstream. Think of it as a close cousin of LDL (the so-called “bad” cholesterol), but with an extra protein attached called apolipoprotein(a). This extra passenger is what makes Lp(a) particularly problematic.

Elevated Lp(a) works against your heart in several ways: it promotes the build-up of fatty plaques in artery walls, encourages blood clots, and drives inflammation in the cardiovascular system. The result is a meaningfully higher risk of heart attack, stroke, aortic valve disease, peripheral artery disease, and even heart failure.

Crucially, this risk exists independently of your LDL cholesterol and other traditional risk factors. It persists across all ethnicities and sexes, and is not neutralised by statin therapy.

What Makes Lp(a) Unusual: It’s Almost Entirely Genetic

More than 90% of your level is determined by your genes, specifically the LPA gene. Diet, exercise, and lifestyle choices have very little influence on it.

This means:

• You can be lean, fit, eat well, and still have dangerously high Lp(a)
• It runs strongly in families — if a parent has high Lp(a), there’s a 50% chance of inheriting elevated levels
• South Asians and people of African descent tend to carry higher average Lp(a) levels

Because it’s genetic, your Lp(a) level remains relatively stable throughout adult life. In most cases, you only need to test it once.

Should You Get Tested?

The new 2026 guidelines say: yes, at least once, for all adults. This is a significant shift from previous guidance, which reserved Lp(a) testing for higher-risk patients only.

Testing is especially important if you have:

• A personal or family history of early heart disease or stroke
• Familial hypercholesterolaemia (an inherited cholesterol condition)
• Calcific aortic valve disease
• Had a cardiovascular event despite seemingly normal cholesterol levels
• South Asian or African ancestry

If you have elevated Lp(a), the guidelines also recommend cascade testing — meaning first-degree family members (parents, siblings, children) should be tested too, given how strongly it runs in families.

Can High Lp(a) Be Treated?

• PCSK9 inhibitors (injectable cholesterol drugs) reduce Lp(a) by roughly 15–30%, and trial data suggests patients with higher Lp(a) may derive particular benefit from them
• Lipoprotein apheresis — a procedure that physically filters Lp(a) from the blood — can reduce levels by 50–85% per session, but effects only last 1–2 weeks and it requires regular repeat treatments. The FDA has approved it for certain very high-risk patients
• Niacin can lower Lp(a) by 25–40%, but its cardiovascular benefit is unproven and it carries significant side effects

Multiple therapies specifically targeting Lp(a) production are in advanced clinical development, with results from major cardiovascular outcomes trials expected in 2026 and beyond.

Conclusion

Lp(a) is a largely inherited, often-overlooked cardiovascular risk factor which raises the risk of heart attack, stroke, and aortic valve disease independently of the cholesterol numbers most of us are used to tracking — and it can affect even people who appear perfectly healthy on a standard blood panel.

The good news: a single blood test can tell you where you stand, levels stay stable over time so you only need it once, and the era of targeted Lp(a) treatments may be closer than you think.

Ask your doctor about an Lp(a) test. It’s a conversation your heart might genuinely thank you for.

Related: Chronic Conditions Screening, Are You Due for a Cholesterol Test?

References

1. Blumenthal RS, Morris PB, Gaudino M, et al. 2026 ACC/AHA/AACVPR/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Dyslipidemia. Journal of the American College of Cardiology. 2026.
2. Writing Committee Members, Blumenthal RS, Morris PB, et al. 2026 ACC/AHA/AACVPR/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Dyslipidemia. Circulation. 2026.
3. Nordestgaard BG, Langsted A. Lipoprotein(a) and Cardiovascular Disease. Lancet. 2024.
4. Reyes-Soffer G, Ginsberg HN, Berglund L, et al. Lipoprotein(a): A Genetically Determined, Causal, and Prevalent Risk Factor for Atherosclerotic Cardiovascular Disease: A Scientific Statement From the American Heart Association. Arteriosclerosis, Thrombosis, and Vascular Biology. 2022.
5. Wong ND, Fan W, Hu X, et al. Lipoprotein(a) and Long-Term Cardiovascular Risk in a Multi-Ethnic Pooled Prospective Cohort. Journal of the American College of Cardiology. 2024.
6. Alebna PL, Han CY, Ambrosio M, et al. Association of Lipoprotein(a) With Major Adverse Cardiovascular Events Across Hs-CRP: A Systematic Review and Meta-Analysis. JACC Advances. 2024.
7. Abbasi J. What to Know About the New Lipid Guidelines. JAMA. 2026.
8. Rader DJ. Targeting Lipoprotein(a) — the Next Frontier in Cardiovascular Disease. New England Journal of Medicine. 2025.
9. Malick WA, Goonewardena SN, Koenig W, Rosenson RS. Clinical Trial Design for Lipoprotein(a)-Lowering Therapies: JACC Focus Seminar 2/3. Journal of the American College of Cardiology. 2023.